Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 53 Neoplasm Metastasis 16 Carcinoma, Non-Small-Cell Lung 10 Neoplasms 7 Brain Neoplasms 5 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasms by Site 3 Melanoma 3 Glioma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Breast Diseases 3 Sarcoma, Ewing 2 Recurrence 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma 2 Glioblastoma 2 Advanced Cancer 2 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Spinal Cord Neoplasms 1 Solid Tumor, Adult 1 Sarcoma 1 Rhabdomyosarcoma 1

Interventions

Fulvestrant 13 Letrozole 6 Anastrozole 5 palbociclib 4 exemestane 3 Injections 3 Docetaxel 3 Paclitaxel 2 Goserelin 2 Dasatinib 2 Capecitabine 2 Alpelisib 2 AZD9833 2 vandetanib 1 ribociclib 1 irinotecan sucrosofate 1 entinostat 1 elacestrant 1 cediranib 1 abemaciclib 1 XMT-1522 1 Vinorelbine 1 Sirolimus 1 Ritonavir 1 Lead 1 Itraconazole 1 Immunotherapy, Adoptive 1 Everolimus 1 Decitabine 1 Combined Modality Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Breast Cancer × abemaciclib × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡